PLX647

Overview

PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC 50 s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC 50 s=91 and 130 nM, respectively).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > c-Fms | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-13838
• CAS No.: 873786-09-5
• Molecular Formula: C21H17F3N4
• Molecular Weight: 382.38
• Purity: 99.74%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution
• Availability: In-stock

Source

Original product source